Publication

M-21: Guideline for Determining Pharmacovigilance Reporting Requirements in North America

Abstract

This publication provides guidance for pharmacovigilance reporting to FDA and Health Canada. This guidance is intended to aid United States and Canadian companies that market common medical gases (i.e., oxygen, nitrogen, medical air, carbon dioxide, nitrous oxide, helium, and carbon monoxide and medically appropriate mixtures thereof) in setting up a pharmacovigilance reporting system that satisfies local and region-al regulatory requirements, bearing in mind any global requirements when applicable.

This publication does not address reporting requirements for gases or medical gas equipment classified as medical devices (materiovigilance).

CGA continues to work with the FDA and Health Canada on pharmacovigilance requirements for common medical gases.

Access Publication

Member Price:
$15
Subscriber Price:
$15
Non-Member Price:
$27

Member E-Pub Price:
$0
Subscriber E-Pub Price:
$0
Non-Member E-Pub Price:
$27
Buy Hard Copy
Purchase E-Pub
View Table of Contents (free)

Properties

Edition:
2
Published:
October 2022
Status:
Available To the Public
Size:
5 pages
Publisher:
CGA
Special Attributes:
Notes:
Committee:
Medical Gases

Cataloging

Category
Medical Gases     Standards & Guidelines
Keywords
medical gases
Related
(none)